Clinical trials: Preterm Infants With White Matter Damage

Preterm Infants With White Matter Damage, Preterm Infants Developing Normally

VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

• Withdrawn
• Age: 25 to 40 weeks
• Observational study

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Trial name

NCT00564161

Sponsor

Hadassah Medical Organization